CLINICAL ROLE -
Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding disease burden and treatment management of indolent relapse and aggressive relapse multiple myeloma.
EP. 1: Defining Indolent Relapse Multiple Myeloma
Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.
EP. 2: Differentiating Treatment Strategies for Indolent Versus Aggressive Relapse MM
Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.
EP. 3: Overview of Current MM Treatment Landscape
Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.
EP. 4: Patient-Specific Factors Influencing MM Treatment Decisions
Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.
EP. 5: Utilizing Three-Drug Regimen in MM Treatment
Experts highlight the use of 3- and 4-drug regimens for managing relapsed refractory multiple myeloma.
EP. 6: Clinical and Operational Differences: Proteasome Inhibitors Versus AntiCD38 Antibody Therapies
Experts navigate the impact of proteasome inhibitors and anti-CD38 antibody therapies in the relapsed refractory multiple myeloma treatment landscape.
EP. 7: Proteosome Inhibitors in Combination Therapy
Experts discuss the role of proteasome inhibitors in combination therapy in the management of relapsed indolent multiple myeloma.
EP. 8: Highlighting the Role of Proteosome Inhibitors in RRMM Treatment Pathways
Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.
EP. 9: Pharmacist Engagement in MM Treatment Landscape
EP. 10: Optimizing Clinical Pathways and Analyzing Quality of Life for Patients with MM
Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.
EP. 11: Social Determinants of Health Impacting RRMM Treatment Landscape
Social determinants of health inhibit optimal impact of MM treatment.
EP. 12: Navigating Adverse Events and Maximizing MM Treatment Adherence
The medical experts discuss strategies to achieve treatment adherence.
EP. 13: Monitoring for Treatment Toxicities Associated with Care for MM
Navigating treatment toxicities is paramount to achieving treatment goals in MM management.
EP. 14: Oncology Pharmacists Influencing the MM Treatment Landscape
Drs Haumschild, Anderson, and Hinojosa provide their closing thoughts regarding treatment considerations for patients with RRMM.
2 Clarke Drive Cranbury, NJ 08512